Abstract: A crystalline silicon carbide fiber containing silicon carbide and boron nitride, the crystalline silicon carbide fiber having a content of Si of 64% to 72% by weight, a content of C of 28% to 35% by weight, and a content of B of 0.1% to 3.0% by weight, and including, at a surface portion, a composition gradient layer in which a content of silicon carbide increases while a content of boron nitride decreases toward a depth direction.

Abstract: This photocurable resin composition contains a polymer cross-linked material (A) and a polymeric material (B), wherein the polymer cross-linked material (A) contains urethane(meth)acrylate, and the polymeric material (B) contains a polyurethane resin that includes a structure derived from polycarbonate polyols and that does not have an acrylic group. This photocurable resin composition has excellent high-temperature adhesion. The urethane(meth)acrylate in the polymer cross-linked material (A) preferably includes a structure derived from polycarbonate polyols.

Abstract: Provided are: a porous polyether sulfone film having macrovoids and having excellent dimensional stability; and a production method therefor. Provided is a porous polyether sulfone film having a surface layer (a), a surface layer (b), and a macrovoid layer interposed between the surface layer (a) and the surface layer (b). The macrovoid layer has a partition wall joined to the surface layers (a) and (b) and a plurality of macrovoids surrounded by the partition wall and the surface layers (a) and (b). The surface layer (a) and the surface layer (b) have pores connected to the macrovoids.

Abstract: The present invention provides a polyamide resin composition capable of simultaneously satisfying, with regard to a molded body, suppression of dimensional change upon water absorption, excellent abrasion resistance after water absorption, excellent impact strength, and high surface strength. The present invention relates to a resin composition comprising a glass fiber having a non-circular cross section, and a polyamide resin having a structural unit having more than 6 carbon atoms per 1 amide group, wherein a number average molecular weight of the polyamide resin is 20000 to 40000, and a content of the glass fiber is 15 mass % to 60 mass %.

Abstract: The present invention relates to a cell culturing method and kit. More specifically, it relates to a cell culturing method and kit using a support that is exposed to the air. It further relates to a method of culturing cells by allowing them to migrate onto a porous polyimide film.

Abstract: Methods of producing a compound represented by formula (I) or a pharmacologically acceptable salt thereof include: wherein L1 is an optionally substituted C1-6 alkylene group or the like, L2 is a single bond or the like, L3 is a single bond or the like, R1, R2, and R3 are each independently an optionally substituted C1-4 alkyl group or the like, R4 is a hydrogen atom or the like, and R5 is a hydrogen atom or the like.

Abstract: The present invention pertains to a porous polyimide film production method and a porous polyimide film produced using said method, said method including: a step (1) in which a poly(amic acid) solution comprising 40%-97% by mass organic polar solvent and 3%-60% by mass poly(amic acid) having an intrinsic viscosity, comprising tetracarboxylic acid units and diamine units, of 1.0-3.0 is cast in film form and immersed in or caused to come in contact with a coagulating solvent having water as an essential component thereof, and a porous film of poly(amic acid) is produced; and a step (2) in which the porous film of poly(amic acid) obtained in said step is heat treated and imidized. Shrinkage in the film longitudinal direction and transverse direction after heat treatment is suppressed to no more than 8% for each direction and the speed of temperature increase in a temperature range of at least 200° C. during the heat treatment is at least 25° C./min.

Abstract: A multilayer tube having excellent low temperature impact resistance, breakage pressure strength at high temperature, flexibility, dimensional stability, and elution resistance of low molecular weight substances and ion components. The multilayer tube has a layer containing an aliphatic polyamide composition having a predetermined range of a bending elastic modulus; a layer containing a modified polyolefin has a melting point over a predetermined temperature, and the aliphatic polyamide composition contains an aliphatic polyamide having a predetermined range of a methylene group/amide group number ratio, an elastomer polymer having a constituent unit derived from a carboxyl group and/or acid anhydride group-containing unsaturated compound, and a plasticizer having a certain structure if necessary; and the thickness of the layer containing the aliphatic polyamide composition is a specific ratio or more of the total wall thickness of the tube.

Abstract: It is provided a multilayer tube having a layer containing a specific aliphatic polyamide composition and a layer containing a semi-aromatic polyamide composition which contains a semi-aromatic polyamide having a specific structure or a mixture thereof, and the both layers being disposed adjacent to each other, wherein the aliphatic polyamide composition contains an aliphatic polyamide having a melting point of a specific value or less, and a ratio of the number of the methylene groups to the number of the amide groups is a specific value or more, an aliphatic polyamide having an absolute value of a difference in solubility parameter SP values to that of the aliphatic polyamide being a specific range, and an elastomer polymer containing a constitutional unit derived from an unsaturated compound having a carboxyl group and/or an acid anhydride group.

Abstract: The present invention provides a compound represented by the general formula (Ia) or a pharmacologically acceptable salt thereof. In the general formula (Ia), two R moieties each independently represent a C1-3 alkyl group or the like; and R1, R2 and R3 each independently represent an optionally substituted linear or branched C1-4 alkyl group.

Abstract: The present invention provides a non-aqueous electrolytic solution for a lithium secondary battery or a lithium ion capacitor, wherein the non-aqueous electrolytic solution includes a lithium salt as dissolved in a non-aqueous solvent in a concentration of 0.8 to 1.5 M (mol/L), the non-aqueous solvent includes, in relation to the whole of the non-aqueous solvent, 5 to 25% by volume of ethylene carbonate, 5 to 25% by volume of propylene carbonate, 20 to 30% by volume of dimethyl carbonate, 20 to 40% by volume of methyl ethyl carbonate, and 10 to 20% by volume of a fluorinated chain ester; the total content of ethylene carbonate and propylene carbonate in the non-aqueous solvent is 20 to 30% by volume, the total content of dimethyl carbonate and the fluorinated chain ester in the non-aqueous solvent is 30 to 40% by volume; and the flash point of the non-aqueous electrolytic solution is 20° C. or higher, and the present invention also provides an energy storage device.

Abstract: A first radiance meter is directed toward an object to be measured, radiance is measured through a space where dust is present with the use of at least two wavelengths by the first radiance meter, second radiance meters which are equal in number to one or more objects having temperatures different from that of the object to be measured are directed toward the objects, radiances are measured through the space with the use of at least two wavelengths by the second radiance meters respectively, and a temperature of the object to be measured, a temperature of the dust, and concentration of the dust are measured from the radiances measured by the first radiance meter and the second radiance meters.

Abstract: The present invention provides a compound that is highly safe and useful in the prevention, alleviation, and/or treatment of various diseases involving enteropeptidase inhibition and/or trypsin inhibition, a pharmaceutical composition containing the compound, a method for producing the compound, and the like. Specifically, the present invention provides a compound represented by the following general formula (I): [wherein: A1 and A2 each independently represent an inhibitor residue having at least one activity selected from an enteropeptidase inhibitory activity and a trypsin inhibitory activity; and Z represents a spacer that links A1 to A2] or a pharmaceutically acceptable salt thereof.

Abstract: A polyolefin porous film is provided, the film comprising a polyethylene-based resin, wherein a weight average molecular weight of the polyethylene-based resin is 450,000 or less, and a content of a high molecular weight component having a molecular weight of 1,000,000 or more in the polyethylene-based resin is 2 to 11% by mass.

Abstract: A polyimide precursor including at least one repeating unit represented by the following chemical formula (1): in which A is an arylene group; and X1 and X2 are each independently hydrogen, an alkyl group having 1 to 6 carbon atoms, or an alkylsilyl group having 3 to 9 carbon atoms, and a polyimide obtained from the polyimide precursor has a coefficient of linear thermal expansion from 50° C. to 400° C. of 100 ppm/K or less.

Abstract: The present invention relates to a method for producing N-substituted sulfonamide compounds including a step of reacting a sulfonamide compound of general formula (1) with a halogenated organic compound of general formula (2) in the presence of cesium carbonate or potassium carbonate in an organic solvent to produce an N-substituted sulfonamide compound of general formula (3).

Abstract: A process for producing nitrogen-rich air by feeding high temperature air at 150° C. or more to an air separation membrane module is described. After being placed at 175° C. for two hours, the air separation module exhibits a shape-retention ratio of 95% or more in one embodiment. The nitrogen-rich air can be fed to a fuel tank for an aircraft, for example.

Abstract: Provided is a lithium titanate powder for an electrode of an energy storage device, wherein the lithium titanate powder includes Li4Ti5O12 as a main component and has a specific surface area of 5 to 50 m2/g, a total-fine pore volume of the lithium titanate powder is 0.03 to 0.5 ml/g and the lithium titanate powder includes a phosphorus atom in an amount of 0.03 to 1% by mass, an active material containing the lithium titanate powder, an electrode sheet containing the active material, and an energy storage device using the electrode sheet.

Abstract: The present invention provides a compound of general formula (I) (wherein, R1, X, p and q are as described in the present description and claims), or a pharmacologically acceptable salt thereof, and a pharmaceutical composition containing that compound.

Abstract: A pharmaceutical composition including a compound represented by the formula (I) or a pharmacologically acceptable salt thereof wherein two R moieties each independently are a C1-3 alkyl group or are groups bonded to each other to form a C2-5 alkylene group; A is an optionally substituted C6-10 aryl group or an optionally substituted heteroaryl group; and R1, R2 and R3 each independently are an optionally substituted linear or branched C1-4 alkyl group, wherein the pharmaceutical composition is administered in combination with an immunotherapeutic agent.